| __timestamp | Intra-Cellular Therapies, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 49315000 |
| Thursday, January 1, 2015 | 18187286 | 75043000 |
| Friday, January 1, 2016 | 24758063 | 83749000 |
| Sunday, January 1, 2017 | 23666957 | 122682000 |
| Monday, January 1, 2018 | 30099855 | 207761000 |
| Tuesday, January 1, 2019 | 64947625 | 284812000 |
| Wednesday, January 1, 2020 | 186363444 | 317875000 |
| Friday, January 1, 2021 | 272611040 | 282660000 |
| Saturday, January 1, 2022 | 358782000 | 451421000 |
| Sunday, January 1, 2023 | 409864000 | 481871000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Sarepta Therapeutics, Inc. over the past decade. From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. Meanwhile, Sarepta Therapeutics experienced a tenfold rise in the same period. Notably, in 2023, Sarepta's SG&A expenses peaked at approximately 482 million, surpassing Intra-Cellular's 410 million. This trend highlights the aggressive expansion and operational scaling within the biotech sector. As these companies continue to innovate, monitoring their financial strategies offers valuable insights into their market positioning and future growth potential.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Sarepta Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Intra-Cellular Therapies, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Analyzing R&D Budgets: Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Corcept Therapeutics Incorporated
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Sarepta Therapeutics, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Wave Life Sciences Ltd. Trends and Insights